Carmen Fajardo
Hospital de La Ribera(ES)
Publications by Year
Research Areas
Pituitary Gland Disorders and Treatments, Growth Hormone and Insulin-like Growth Factors, Adrenal and Paraganglionic Tumors, Adrenal Hormones and Disorders, Neuroendocrine Tumor Research Advances
Most-Cited Works
- → Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial(2021)603 cited
- → Clinical Characteristics and Therapeutic Responses in Patients with Germ-LineAIPMutations and Pituitary Adenomas: An International Collaborative Study(2010)365 cited
- → Aryl Hydrocarbon Receptor-Interacting Protein Gene Mutations in Familial Isolated Pituitary Adenomas: Analysis in 73 Families(2007)321 cited
- → Acromegaly at diagnosis in 3173 patients from the Liège Acromegaly Survey (LAS) Database(2017)239 cited
- → High prevalence of AIP gene mutations following focused screening in young patients with sporadic pituitary macroadenomas(2011)168 cited
- → Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial(2017)165 cited
- → Expression of aryl hydrocarbon receptor (AHR) and AHR-interacting protein in pituitary adenomas: pathological and clinical implications(2009)144 cited
- → Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: Results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study(2005)94 cited
- → Cyclin-dependent kinase inhibitor 1B (CDKN1B) gene variants in AIP mutation-negative familial isolated pituitary adenoma kindreds(2012)86 cited
- → Less weight gain and hypoglycaemia with once‐daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients—The PREDICTIVE™ BMI clinical trial1(2008)79 cited